US 11,944,669 B2
Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
Michael Kaleko, Rockville, MD (US); Sheila Connelly, Rockville, MD (US); and Vincent John Wacher, Rockville, MD (US)
Assigned to Theriva Biologics, Inc., Rockville, MD (US)
Filed by Theriva Biologics, Inc., Rockville, MD (US)
Filed on Feb. 2, 2023, as Appl. No. 18/163,648.
Application 18/163,648 is a continuation of application No. 16/998,304, filed on Aug. 20, 2020, granted, now 11,596,674.
Application 16/998,304 is a continuation of application No. 16/031,266, filed on Jul. 10, 2018, granted, now 10,792,346, issued on Oct. 6, 2020.
Application 16/031,266 is a continuation of application No. 15/641,806, filed on Jul. 5, 2017, granted, now 10,046,035, issued on Aug. 14, 2018.
Application 15/641,806 is a continuation of application No. 14/757,522, filed on Dec. 23, 2015, granted, now 9,744,221, issued on Aug. 29, 2017.
Claims priority of provisional application 62/256,994, filed on Nov. 18, 2015.
Claims priority of provisional application 62/096,202, filed on Dec. 23, 2014.
Prior Publication US 2023/0405099 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/50 (2006.01); A61K 9/16 (2006.01); A61K 9/50 (2006.01); A61K 31/4164 (2006.01); A61K 31/424 (2006.01); A61K 31/43 (2006.01); A61K 31/7056 (2006.01); A61K 35/74 (2015.01); A61K 35/741 (2015.01); A61K 38/14 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/50 (2013.01) [A61K 9/1652 (2013.01); A61K 9/5078 (2013.01); A61K 31/4164 (2013.01); A61K 31/424 (2013.01); A61K 31/43 (2013.01); A61K 31/7056 (2013.01); A61K 35/74 (2013.01); A61K 35/741 (2013.01); A61K 38/14 (2013.01); A61K 45/06 (2013.01); A61K 9/5026 (2013.01); A61K 9/5047 (2013.01); C12Y 305/02006 (2013.01)] 19 Claims
 
1. A formulation comprising a beta-lactamase, wherein the formulation comprises at least one particle with each particle comprising:
about 0.5-2.5% beta-lactamase;
about 0.1-1% hydroxypropylmethylcellulose acetate succinate (HPMCAS);
about 5-15% ethylcellulose dispersion;
about 0.1-1% sodium stearyl fumarate;
about 0.1-1% buffer; and
about 80-90% water.